Every 8-K that QuidelOrtho Corporation (QDEL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow QDEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QDEL filings page.
QuidelOrtho Corporation (QDEL) amended its existing credit agreement on September 23, 2026, resetting financial covenant levels through the fiscal quarter ending September 30, 2029. The maximum Consolidated Leverage Ratio and minimum Consolidated Interest Coverage Ratio are 5.50 to 1.00 and 2.25 to 1.00, respectively, on or prior to July 2, 2028; 5.00 and 2.50 on October 1 or December 31, 2028; 4.50 and 2.75 on April 1 or July 1, 2029; and 4.25 and 3.00 on or after September 30, 2029.
Initial rates for the Term Loan A Facilities and Revolving Credit Facility run from the Amendment effective date until the first business day after the Administrative Agent receives the compliance certificate for the quarter ending September 28, 2026: 1.50% per annum for base-rate loans and 2.50% for Term SOFR loans. Thereafter, leverage-based ranges are 0.75% to 2.00% for base-rate loans and 1.75% to 3.00% for Term SOFR loans; the unused commitment fee ranges from 0.20% to 0.40% per annum. Term Loan B interest is unchanged.
QuidelOrtho reported second quarter 2026 results with total revenue of $630.9 million, a 2.8% year-over-year increase, and a GAAP net loss of $92.9 million, or a loss of $1.36 per diluted share. Adjusted EBITDA was $129.3 million, a 20.5% margin, as Labs revenue grew 4% and Point of Care revenue grew 16%.
Revenue excluding China rose 6.1%, while China revenue declined 18.7%, reflecting pressure from proposed In Vitro Diagnostics pricing changes. QuidelOrtho cut its 2026 outlook to $2.52–$2.60 billion in revenue, $540–$560 million in adjusted EBITDA and $0.65–$0.90 adjusted EPS, and withdrew free cash flow guidance after using $143.6 million of operating cash in the first half.
QuidelOrtho Corporation is appointing Micah Young as Chief Financial Officer and principal financial officer, effective July 6, 2026, succeeding retiring CFO Joseph M. Busky, who will remain through the transition and then serve as a special advisor.
Young, a seasoned medical technology finance executive and former CFO of Masimo Corporation, will receive a $750,000 annual base salary, an annual target cash bonus equal to 100% of base salary, a $500,000 cash sign-on bonus, and a one-time inducement grant of RSUs valued at $6,500,000 vesting over three years. He is also expected to receive 2027 equity grants valued at $5,000,000, split between time-based RSUs and stock options, along with severance and change-in-control protections consistent with other executives.
Busky will receive an annual base salary of $340,000 for six months after the effective date during the transition, then up to 24 months as special advisor at $100,000 per year, with continued eligibility for 2026 bonus and existing equity vesting terms.
QuidelOrtho Corporation reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. Stockholders elected all ten director nominees, each receiving over 56 million votes in favor, with several receiving more than 56.6 million votes for and relatively few votes withheld.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, with 55,716,067 votes for, 1,486,910 against, and 22,228 abstentions, alongside 7,088,721 broker non-votes. In addition, they ratified the appointment of KPMG LLP as independent registered public accounting firm for the 2026 fiscal year, with 64,197,113 votes for, 97,367 against, and 19,446 abstentions.
QuidelOrtho Corporation reported weaker first quarter 2026 results with lower revenue, higher losses and reduced full-year guidance. Total revenue was $619.8 million, down 10.5% from $692.8 million a year earlier. Point of Care revenue fell 34% to $112.8 million, mainly from a weaker respiratory season, while Labs revenue declined 5.3% to $353.1 million amid slower China distributor sales, Middle East disruption and the end of a Grifols arrangement. Immunohematology grew 7.6% to $138.3 million.
GAAP net loss widened to $91.8 million from $12.7 million, with GAAP diluted loss per share of $1.35 versus $0.19. Adjusted EBITDA fell to $108.7 million from $159.8 million, and adjusted EBITDA margin declined to 17.5% from 23.1%.
For full-year 2026, the company now expects total revenue of $2.70–$2.75 billion, adjusted EBITDA of $615–$630 million, adjusted diluted EPS of $1.80–$2.00 and free cash flow of $100–$120 million, all lower than prior guidance. Management highlighted the April acquisition of LEX Diagnostics and new assay and platform launches as key elements of its long-term growth strategy.
QuidelOrtho Corporation released preliminary unaudited results showing first quarter 2026 revenue of $615–$620 million, reflecting a weaker respiratory season, slower distributor sales in China tied to proposed reimbursement cuts, and EMEA order delays related to the Middle East conflict.
The company expects first quarter 2026 free cash flow of $(65) to $(70) million and continues to anticipate positive free cash flow for full-year 2026. Management believes the low end of its previously issued full-year 2026 financial guidance remains achievable and plans to discuss this outlook with full results on May 5, 2026.
QuidelOrtho Corporation announced a planned leadership transition in its top legal role. Chief Legal Officer and Corporate Secretary Michelle A. Hodges will retire from these positions effective March 23, 2026, with a transition and retirement agreement supporting an orderly handover of her duties.
For up to six months, Ms. Hodges will continue receiving her current base salary and benefits while transitioning responsibilities. She will then serve as special advisor to the Chief Executive Officer for up to twenty-four months, initially at her current base salary rate, which will be reduced by 50% for the remainder of the advisory term, while remaining eligible for employee benefits, annual bonus and equity grant opportunities, and continued vesting of existing equity awards.
The Board of Directors appointed Nathaniel “Nate” Sisitsky as the new Chief Legal Officer and Corporate Secretary, effective as of the same date. With more than 25 years of legal and governance experience at public life sciences and technology companies, including prior Chief Legal Officer and Corporate Secretary roles, he will lead QuidelOrtho’s global legal, compliance and corporate governance functions.
QuidelOrtho Corporation reported that its Chief Financial Officer and principal financial officer, Joseph M. Busky, has informed the company of his plans to retire, effective June 30, 2026. The company states that his decision is for personal reasons and not due to any disagreement regarding financial statements, operations, policies, or practices. This advance notice gives QuidelOrtho time to manage the transition in its senior financial leadership.
QuidelOrtho Corporation reported fourth-quarter and full-year 2025 results and issued 2026 guidance. Full-year 2025 revenue was $2.73 billion, slightly below 2024, as respiratory revenue fell 20% to $402.1 million with lower COVID-19 testing, while non-respiratory revenue reached $2.33 billion.
The company posted a 2025 GAAP net loss of $1.13 billion and a GAAP operating loss of $0.92 billion, driven largely by a $701 million non-cash goodwill impairment charge. Despite this, adjusted EBITDA was $597 million with a 22% adjusted EBITDA margin, a 240 basis point improvement.
Free cash flow was $(77) million in 2025, reflecting one-time ERP system investments, but management expects free cash flow to improve by over $200 million in 2026, guiding to $120–$160 million. 2026 guidance calls for $2.7–$2.9 billion in revenue, adjusted EBITDA of $630–$670 million, and adjusted EPS of $2.00–$2.42. The company also announced that Chief Financial Officer Joseph M. Busky plans to retire effective June 30, 2026.
QuidelOrtho Corporation reported that board member Matthew W. Strobeck has decided not to stand for re-election at the company’s 2026 annual stockholders meeting. He will remain on the board until that meeting, after which the board size will decrease from eleven to ten directors. The company states that his decision is due to other professional commitments and not any dispute or disagreement with the company, its board, or management over operations, policies, or practices.
QuidelOrtho Corporation furnished a stockholder letter via an 8-K. The letter from President and CEO Brian J. Blaser provides an update on results for the third quarter ended September 28, 2025 and is included as Exhibit 99.1.
The information, including Exhibit 99.1, is being furnished and is not deemed “filed” under the Exchange Act, which means it is not subject to Section 18 liability and is not incorporated by reference into other filings. The report was signed by CFO Joseph M. Busky. QuidelOrtho’s common stock trades on Nasdaq under the symbol QDEL.
QuidelOrtho Corporation furnished an 8-K announcing its financial results for the third quarter ended September 28, 2025, and an earnings conference call. The company will host the call at 2:00 p.m. Pacific Time on November 5, 2025. A press release with the results is furnished as Exhibit 99.1. The information is furnished and not deemed filed under the Exchange Act.
QuidelOrtho Corporation disclosed that it entered into a Credit Agreement dated Aug 21, 2025 under which the company is the borrower and Bank of America, N.A. serves as administrative agent and swing line lender, with other lenders and letter-of-credit issuers participating. The filing incorporates Item 1.01 information by reference and attaches the Credit Agreement as Exhibit 10.1. A press release dated Aug 21, 2025 and embedded Inline XBRL cover page data are also noted. The filing is signed by the company’s CFO, indicating the agreement is a disclosed material event; specific financial terms, committed facility size, covenants, maturity, and pricing are not provided in the text available.